Publications

Peer-Reviewed Original Research Articles 2009-Present

1. Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PH. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat 158(3):441-54, 8/2016. e-Pub 7/2016. PMID: 27393618.
   
2. den Hollander P, Rawls K, Tsimelzon A, Shepherd J, Mazumdar A, Hill J, Fuqua SA, Chang JC, Osborne CK, Hilsenbeck SG, Mills GB, Brown PH. Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival. Cancer Res 76(7):1942-53, 4/2016. e-Pub 2/2016. PMCID: PMC4873402.
3. Shepherd JH, Uray IP, Mazumdar A, Tsimelzon A, Savage M, Hilsenbeck SG, Brown PH. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget 7(11):13106-21, 3/2016. e-Pub 2/2016. PMID: 26894864.
4. Zhao J, Zhao D, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB, Brown PH. Death-associated protein kinase 1 promotes growth of p53-mutant cancers. J Clin Invest 125(7):2707-20, 7/2015. e-Pub 6/2015. PMCID: PMC4563671.
5. Haricharan S, Brown PH. TLR4 has a TP53-Dependent Dual Role in Regulating Breast Cancer Cell Growth. Proc Natl Acad Sci U S A 112(25):E3216-25, 6/2015. e-Pub 6/2015. PMCID: PMC4485113.
6. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer. Clin Cancer Res 21(7):1688-98, 4/2015. e-Pub 9/2014. PMCID: PMC4362882.
7. Haricharan S, Bainbridge MN, Scheet P, Brown PH. Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. Breast Cancer Res Treat 146(1):211-20, 7/2014. e-Pub 5/2014. PMCID: PMC4061465.
8. Litzenburger BC, Brown PH. Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. Curr Breast Cancer Rep 6:96-109, 6/2014. e-Pub 3/2014. PMCID: PMC4015058.
9. den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol 3:250, 2013. e-Pub 9/2013. PMCID: PMC3780469.
10. Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PH. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the pro-inflammatory cytokines IL-6 and IL-8. Cancer Res 73(11):3470-80, 6/2013. e-Pub 4/2013. PMCID: PMC3853111.
11. Mazumdar A, Medina D, Kittrell FS, Zhang Y, Hill JL, Edwards DE, Bissonnette RP, Brown PH. The Combination of Tamoxifen and the Rexinoid LG100268 Prevents ER-Positive and ER-Negative Mammary Tumors in P53-Null Mammary Gland Mice. Cancer Prev Res (Phila) 5(10):1195-202, 10/2012. e-Pub 8/2012. PMCID: PMC3837417.
    
12. Wang C, Uray IP, Mazumdar A, Mayer JA, Brown PH. SLC22A5/OCTN2 Expression in Breast Cancer is Induced by Estrogen via a Novel Intronic Estrogen-Response Element (ERE). Breast Cancer Res Treat 134(1):101-15, 7/2012. e-Pub 1/2012. PMCID: PMC3416040.
    
13. Uray IP, Rodenberg JM, Bissonnette RP, Brown PH, Mancini MA. Cancer Preventive Rexinoid Modulates Neutral Lipid Content of Mammary Epithelial Cells through a PPAR-Gamma dependent Mechanism. Mol Pharmacol 81(2):228-38, 2/2012. e-Pub 11/2011. PMCID: PMC3263950.
    
14. Uray IP, Brown PH. Chemoprevention of Hormone Receptor-negative Breast Cancer: New Approaches Needed. Recent Results Cancer Res(188):147-62, 2011.
15. Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M, Brown PH. Estrogen Induces c-myc Gene Expression via an Upstream Enhancer Activated by the Estrogen Receptor and the AP-1 Transcription Factor. Mol Endocrinol 25(9):1527-38, 2011. PMCID: PMC3165912.
16. Gonzalez-Angulo AM, Hennessy BY, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Lei D, Broaddus R, Lluch AM, Aparicio S, Brown P, Pusztai L, Symmans F, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 8(1):11, 2011. PMCID: PMC3170272.
17. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 12(3):R40. e-Pub 6/2010. PMCID: PMC2917035.
18. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119(2):305-14, 2010.
19. Johnson KA, Brown PH. Drug Development for Cancer Chemoprevention: Focus on Molecular Targets. Semin Oncol 37(4):345-58, 2010.
20. Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, Kim HT, Gilmer TM, Sexton KR, Hilsenbeck SG, Osborne CK, Brown PH. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst 101(2):107-13, 2009. PMCID: PMC2639315.
21. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown PH. Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor-Negative Breast Cancer. Clin Cancer Res 15(20):6327-40, 2009. PMCID: PMC2763053.
22. Chen L, Krisko TI, Speers CW, Reif D, Brown PH. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Research 1:69(23):8853-61, 2009. PMCID: PMC2830975.
23. Uray IP, Shen Q, Seo HS, Kim H, Lamph WW, Bissonnette RP, Brown PH. Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. J Biol Chem 284(1):345-53, 2009. PMCID: PMC2610495.